Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Abstract Background Long-term antiviral treatments are associated with a significantly lower hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients by reducing HBV DNA concentrations. However, it is still controversial whether antiviral strategies affect HCC development in an...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2022-03-01
Edice:	BMC Cancer
Témata:	Chronic hepatitis B Hepatocellular carcinoma Entecavir Tenofovir Cirrhosis
On-line přístup:	https://doi.org/10.1186/s12885-022-09413-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!